Improving the Management of Patients on Oral Regimens

Conference Correspondent - TON - ASH 2015 - Multiple Myeloma, Conference Correspondent
Beth Faiman, PhD, APRN-BC, AOCN
Editor in Chief

Beth Faiman elaborates on her idea wish list of resources and tools that would help her to better manage patients on oral oncolytics.

I often think of what my wish list would be for in a perfect world, how I would manage patients on in all oral regimen. If I could have somebody that could create calendars for may patients.

We have lots of tools that auto‑populate. But with these complex regimens, it's a challenge to get the dates right. If they miss a dose, how does that address? If I could have somebody to create a calendar or tool to help manage, that would be great.

The pharmaceutical companies and the pharmacies have staff, as I mentioned before, that help remind me to refill. Because remember these drugs are dosed, most of them at a monthly basis. At the end of each month, many of the drugs have to be refilled.

If there is a delay in dispensing on my end and a delay in dispensing on the pharmacy end, then that could put the patients off schedule. Keeping those resources available, those reminders available help me to do my job and help the patient get what they need.

Related Items
Staying Abreast of New Treatments
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
Managing Patients with Multiple Myeloma
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
Perceptions of Daratumumab Therapy
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
Starting a Patient on Daratumumab
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
What Do Patients Ask About Daratumumab?
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
Unmet Needs in Patients with Myeloma
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
The Challenge of Managing Treatment-Related Toxicites
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
Self-Managing Side Effects
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
Concerns Over New Multiple Myeloma Therapies
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
How Janssen CarePath Helps Patients
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
Last modified: February 10, 2016